Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Single arm, monocentric trial to assess the safety and the progression-free survival related
to the combined treatment of dendritic cell vaccine loaded with autologous tumor homogenate
and temozolomide in patients operated for glioblastoma and then treated with standard
radiochemotherapy (according to Stupp regimen).
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori